{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:19:09Z","timestamp":1794917949537,"version":"4.9.1"},"reference-count":70,"publisher":"Bentham Science Publishers Ltd.","issue":"11","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMM"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n<jats:title>Introduction:<\/jats:title>\n<jats:p>Aminoglycosides are among the first-choice antibiotics for\nroutine clinical use. However, dose-limiting factors such as ototoxicity and nephrotoxicity\nare considered as serious complications of aminoglycosides.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>In this systematic review, the main goal was to investigate the efficacy and\nincidence of nephrotoxicity and ototoxicity of once-daily dosing (ODD) and multiple daily\ndosing (MDD) regimens of aminoglycosides through available randomized controlled\ntrials (RCTs).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>We performed a literature-based research in relevant databases, including\nEMBASE, MEDLINE, and SCOPUS published between 1987 and 2023 using the\nkeywords \u201caminoglycosides\u201d, \u201cpharmacokinetics\u201d, \u201cODD\u201d, \u201cMDD\u201d, \u201conce daily\u201d, \u201cmultiple\ndaily\u201d, \u201cdosing regimen\u201d, \u201cnephrotoxicity\u201d, \u201cototoxicity\u201d, \u201cefficacy\u201d, \u201csafety\u201d, and \u201ctoxicity\u201d.\nAs so told, the results of this article were limited to papers available in English. Our initial\nsearch yielded 1124 results. After a review of the titles and abstracts of the articles, 803\narticles were excluded from this study because they did not address the toxicity and\neffectiveness of ODD versus MDD of aminoglycosides. A total number of 20 studies on\ngentamicin, tobramycin, netilmicin, and amikacin met the inclusion criteria for the\nefficacy of aminoglycosides and their role in ototoxicity and nephrotoxicity were included\nin this review. Studies recruited different age classes, and the age of relevant cohorts\nvaried from only a few days to more than 70 years.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The most common clinical\ncondition in the included studies was cystic fibrosis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>In most studies, there were no significant differences between the two\nregimens regarding ototoxicity. In addition, the ODD regimens were safer than MDD\nconcerning nephrotoxicity.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1566524023666230801160452","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T05:12:09Z","timestamp":1691039529000},"page":"1358-1373","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Aminoglycosides: Single- or Multiple-daily Dosing? An Updated Qualitative Systematic Review of Randomized Trials on Toxicity and Efficacy"],"prefix":"10.2174","volume":"24","author":[{"given":"Iman","family":"Karimzadeh","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghdad","family":"Abdollahpour-Alitappeh","sequence":"additional","affiliation":[{"name":"Cellular and Molecular Biology Research Center, Larestan University of Medical Sciences, Larestan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shokouh","family":"Ghaffari","sequence":"additional","affiliation":[{"name":"Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motahareh","family":"Mahi-Birjand","sequence":"additional","affiliation":[{"name":"Department of\nClinical Pharmacy, School of Pharmacy, Infectious Diseases Research Center, Birjand University of Medical\nSciences, Birjand, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Barkhordari","sequence":"additional","affiliation":[{"name":"Cellular and Molecular Research Center, Gerash University of Medical Sciences,\nGerash, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Effat","family":"Alemzadeh","sequence":"additional","affiliation":[{"name":"Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"7591","DOI":"10.1039\/C4CS00426D","volume":"44","author":"Elshahawi SI","year":"2015","unstructured":"Elshahawi SI; Shaaban KA; Kharel MK; Thorson JSJCSR; A comprehensive review of glycosylated bacterial natural products. Chem Soc Rev  2015,44((21)),7591-697","journal-title":"Chem Soc Rev"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"7411","DOI":"10.3390\/ijms21197411","volume":"21","author":"Dezanet C.","year":"2020","unstructured":"Dezanet C.; Kempf J.; Mingeot-Leclercq M.P.; D\u00e9cout J.L.; Amphiphilic aminoglycosides as medicinal agents. Int J Mol Sci  2020,21(19),7411","journal-title":"Int J Mol Sci"},{"key":"ref=3","first-page":"13","author":"Bryskier A.","year":"2005","unstructured":"Bryskier A.;  American Society of Microbiology  2005,13-38","journal-title":"American Society of Microbiology"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1007\/978-3-319-46718-4_14","volume":"44","author":"Serio A.W.","year":"2000","unstructured":"Serio A.W.; Magalh\u00e3es M.L.; Blanchard J.S.; Connolly L.E.; Aminoglycosides: Mechanisms of Action and Resistance Antimicrobial Drug Resistance. Antimicrob Agents Chemother  2000,44(12),3249-3256","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-1-4939-3323-5_9","author":"Bowers D.R.","year":"2016","unstructured":"Bowers D.R.; Schilling A.N.; Tam V.H.;  Antibiotic Pharmacodynamics  2016,199-220","journal-title":"Antibiotic Pharmacodynamics"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"14570","DOI":"10.1073\/pnas.0903619106","volume":"106","author":"Lee S.","year":"2009","unstructured":"Lee S.; Hinz A.; Bauerle E.; Targeting a bacterial stress response to enhance antibiotic action. Proc Natl Acad Sci  2009,106(34),14570-14575","journal-title":"Proc Natl Acad Sci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"F617","DOI":"10.1152\/ajprenal.00130.2003","volume":"286","author":"Sandoval R.M.","year":"2004","unstructured":"Sandoval R.M.; Molitoris B.A.; Gentamicin traffics retrograde through the secretory pathway and is released in the cytosol via the endoplasmic reticulum. Am J Physiol Renal Physiol  2004,286(4),F617-F624","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/j.1445-5994.2011.02452.x","volume":"41","author":"Avent M.L.","year":"2011","unstructured":"Avent M.L.; Rogers B.A.; Cheng A.C.; Paterson D.L.; Current use of aminoglycosides: Indications, pharmacokinetics and monitoring for toxicity. Intern Med J  2011,41(6),441-449","journal-title":"Intern Med J"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/MOO.0b013e32833e05ec","volume":"18","author":"Warchol M.E.","year":"2010","unstructured":"Warchol M.E.; Cellular mechanisms of aminoglycoside ototoxicity. Curr Opin Otolaryngol Head Neck Surg  2010,18(5),454-458","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1039\/c1ib00034a","volume":"3","author":"Karasawa T.","year":"2011","unstructured":"Karasawa T.; Steyger P.S.; Intracellular mechanisms of aminoglycoside-induced cytotoxicity. Integr Biol  2011,3(9),879-886","journal-title":"Integr Biol"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s00253-005-0279-0","volume":"70","author":"Jana S.","year":"2006","unstructured":"Jana S.; Molecular understanding of aminoglycoside action and resistance. Appl Microbiol Biotechnol  2006,70(2),140-150","journal-title":"Appl Microbiol Biotechnol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1039\/C4MD00163J","volume":"5","author":"Fosso M.Y.","year":"2014","unstructured":"Fosso M.Y.; Li Y.; Garneau-Tsodikova S.; New trends in the use of aminoglycosides. MedChemComm  2014,5(8),1075-1091","journal-title":"MedChemComm"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ijantimicag.2008.09.001","volume":"33","author":"Durante-Mangoni E.","year":"2009","unstructured":"Durante-Mangoni E.; Grammatikos A.; Utili R.; Falagas M.E.; Do we still need the aminoglycosides? Int J Antimicrob Agents  2009,33(3),201-205","journal-title":"Int J Antimicrob Agents"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1136\/thx.2009.131532","volume":"65","author":"Prayle A.","year":"2010","unstructured":"Prayle A.; Watson A.; Fortnum H.; Smyth A.; Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis. Thorax  2010,65(7),654-658","journal-title":"Thorax"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1001\/jamapediatrics.2022.0187","volume":"176","author":"McDermott J.H.","year":"2022","unstructured":"McDermott J.H.; Mahaveer A.; James R.A.; Rapid point-of-care genotyping to avoid aminoglycoside-induced ototoxicity in neonatal intensive care. JAMA Pediatr  2022,176(5),486-492","journal-title":"JAMA Pediatr"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s12325-023-02436-x","volume":"40","author":"Le T.A.","year":"2023","unstructured":"Le T.A.; Hiba T.; Chaudhari D.; Aminoglycoside-related nephrotoxicity and ototoxicity in clinical practice: A review of pathophysiological mechanism and treatment options. Adv Ther  2023,40(4),1357-1365","journal-title":"Adv Ther"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1503\/cmaj.140339","volume":"13","author":"Leis J.A.","year":"2015","unstructured":"Leis J.A.; Rutka J.A.; Gold W.L.; Aminoglycoside-induced ototoxicity. Curr Pharm Des  2015,13(1),119-126","journal-title":"Curr Pharm Des"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"937861","DOI":"10.1155\/2011\/937861","volume":"2011","author":"Huth M.","year":"2011","unstructured":"Huth M.; Ricci A.; Cheng A.; Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. Int J Otolaryngol  2011,2011,937861","journal-title":"Int J Otolaryngol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"692762","DOI":"10.3389\/fncel.2021.692762","volume":"15","author":"Fu X.","year":"2021","unstructured":"Fu X.; Wan P.; Li P.; Mechanism and prevention of ototoxicity induced by aminoglycosides. Front Cell Neurosci  2021,15,692762","journal-title":"Front Cell Neurosci"},{"key":"ref=20","author":"Ricci AJ","year":"2016","unstructured":"Ricci AJ; Greenhouse RJ; Cheng AG; Aminoglycoside antibiotics with reduced ototoxicity.  2016"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.heares.2011.05.008","volume":"281","author":"Xie J.","year":"2011","unstructured":"Xie J.; Talaska A.E.; Schacht J.; New developments in aminoglycoside therapy and ototoxicity. Hear Res  2011,281(1-2),28-37","journal-title":"Hear Res"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jinf.2021.05.010","volume":"83","author":"Dillard L.K.","year":"2021","unstructured":"Dillard L.K.; Martinez R.X.; Perez L.L.; Fullerton A.M.; Chadha S.; McMahon C.M.; Prevalence of aminoglycoside-induced hearing loss in drug-resistant tuberculosis patients: A systematic review. J Infect  2021,83(1),27-36","journal-title":"J Infect"},{"key":"ref=23","first-page":"34894231176333","author":"Kalmanson O.A.","year":"2022","unstructured":"Kalmanson O.A.; McLoughlin K.C.; Kiser T.H.; Gubbels S.P.; Debilitating gentamicin ototoxicity: Case report and recommendations against routine use in surgical prophylaxis. Ann Otol Rhinol Laryngol  2022,34894231176333","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2147\/IMCRJ.S336259","volume":"14","author":"Mantefardo B.","year":"2021","unstructured":"Mantefardo B.; Sisay G.; Case Report: Kanamycin ototoxicity and MDR-TB treatment regimen. Int Med Case Rep J  2021,14,815-817","journal-title":"Int Med Case Rep J"},{"key":"ref=25","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-75613-4","author":"Vinks A.A.","year":"2014","unstructured":"Vinks A.A.; Derendorf H.; Mouton J.W.;  Fundamentals of antimicrobial pharmacokinetics and pharmacodynamics  2014","journal-title":"Fundamentals of antimicrobial pharmacokinetics and pharmacodynamics"},{"key":"ref=26","author":"Fligor B.J.","year":"2013","unstructured":"Fligor B.J.;  Ed Early Diagnosis and Management of Hearing Loss in Medically Fragile Children Seminars in Hearing  2013","journal-title":"Ed Early Diagnosis and Management of Hearing Loss in Medically Fragile Children Seminars in Hearing"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/0897190014546836","volume":"27","author":"Wargo K.A.","year":"2014","unstructured":"Wargo K.A.; Edwards J.D.; Aminoglycoside-induced nephrotoxicity. J Pharm Pract  2014,27(6),573-577","journal-title":"J Pharm Pract"},{"key":"ref=28","first-page":"111","author":"Nolin T.D.","year":"2010","unstructured":"Nolin T.D.; Himmelfarb J.;  Mechanisms of drug-induced nephrotoxicity Adverse drug reactions  2010,111-130","journal-title":"Mechanisms of drug-induced nephrotoxicity Adverse drug reactions"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/ki.2010.337","volume":"79","author":"Lopez-Novoa J.M.","year":"2011","unstructured":"Lopez-Novoa J.M.; Quiros Y.; Vicente L.; Morales A.I.; Lopez-Hernandez F.J.; New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int  2011,79(1),33-45","journal-title":"Kidney Int"},{"key":"ref=30","first-page":"743","volume":"78","author":"Naughton C.A.","year":"2008","unstructured":"Naughton C.A.; Drug-induced nephrotoxicity. Am Fam Physician  2008,78(6),743-750","journal-title":"Am Fam Physician"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1128\/AAC.01314-10","volume":"55","author":"Drusano G.L.","year":"2011","unstructured":"Drusano G.L.; Louie A.; Optimization of aminoglycoside therapy. Antimicrob Agents Chemother  2011,55(6),2528-2531","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1128\/AAC.01430-08","volume":"53","author":"Oliveira J.F.P.","year":"2009","unstructured":"Oliveira J.F.P.; Silva C.A.; Barbieri C.D.; Oliveira G.M.; Zanetta D.M.T.; Burdmann E.A.; Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units. Antimicrob Agents Chemother  2009,53(7),2887-2891","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","volume":"367","author":"Inker L.A.","year":"2012","unstructured":"Inker L.A.; Schmid C.H.; Tighiouart H.; Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med  2012,367(1),20-29","journal-title":"N Engl J Med"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1093\/clinids\/24.5.810","volume":"24","author":"Hatala R.","year":"1997","unstructured":"Hatala R.; Dinh T.T.; Cook D.J.; Single daily dosing of aminoglycosides in immunocompromised adults: A systematic review. Clin Infect Dis  1997,24(5),810-815","journal-title":"Clin Infect Dis"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1128\/AAC.39.3.650","volume":"39","author":"Nicolau D.P.","year":"1995","unstructured":"Nicolau D.P.; Freeman C.D.; Belliveau P.P.; Nightingale C.H.; Ross J.W.; Quintiliani R.; Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother  1995,39(3),650-655","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2288-8-45","volume":"8","author":"Thomas J.","year":"2008","unstructured":"Thomas J.; Harden A.; Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Med Res Methodol  2008,8(1),45","journal-title":"BMC Med Res Methodol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1093\/jac\/dkp330","volume":"64","author":"Tiwari S.","year":"2009","unstructured":"Tiwari S.; Rehan H.S.; Chandra J.; Mathur N.N.; Singh V.; Efficacy and safety of a single daily dose of gentamicin in hospitalized Indian children: A quasi-randomized trial. J Antimicrob Chemother  2009,64(5),1096-1101","journal-title":"J Antimicrob Chemother"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"e569","DOI":"10.1016\/j.ijid.2011.04.012","volume":"15","author":"P\u00e9rez V.","year":"2011","unstructured":"P\u00e9rez V.; Sa\u00e9nz D.; Madriz J.; A double-blind study of the efficacy and safety of multiple daily doses of amikacin versus one daily dose for children with perforated appendicitis in Costa Rica. Int J Infect Dis  2011,15(8),e569-e575","journal-title":"Int J Infect Dis"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1365-2710.2009.01152.x","volume":"36","author":"Abdel-Hady E.","year":"2011","unstructured":"Abdel-Hady E.; El Hamamsy M.; Hedaya M.; Awad H.; The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis. J Clin Pharm Ther  2011,36(1),45-52","journal-title":"J Clin Pharm Ther"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000329842","volume":"119","author":"Buchholtz K.","year":"2011","unstructured":"Buchholtz K.; Larsen C.T.; Schaadt B.; Hassager C.; Bruun N.E.; Once versus twice daily gentamicin dosing for infective endocarditis: a randomized clinical trial. Cardiology  2011,119(2),65-71","journal-title":"Cardiology"},{"key":"ref=41","first-page":"13","volume":"48","author":"Solorzano-Santos F.","year":"1996","unstructured":"Solorzano-Santos F.; Miranda-Novales M.; Diaz-Pena R.; Bernaldez-R\u00edos R.; D\u00edaz-Bensussen S.; Rivera-M\u00e1rquez H.; Amikacin in single daily doses in children with fever. Clin Nutr  1996,48(1),13-18","journal-title":"Clin Nutr"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1097\/01.CCM.0000134832.11144.CB","volume":"32","author":"Olsen K.M.","year":"2004","unstructured":"Olsen K.M.; Rudis M.I.; Rebuck J.A.; Effect of once-daily dosing vs. multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity. Crit Care Med  2004,32(8),1678-1682","journal-title":"Crit Care Med"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s15010-009-8117-4","volume":"37","author":"Riethmueller J.","year":"2009","unstructured":"Riethmueller J.; Ballmann M.; Schroeter T.W.; Tobramycin once- vs thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients. Infection  2009,37(5),424-431","journal-title":"Infection"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1128\/AAC.00995-05","volume":"50","author":"Mulheran M.","year":"2006","unstructured":"Mulheran M.; Hyman-Taylor P.; Tan K.H.V.; Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients. Antimicrob Agents Chemother  2006,50(7),2293-2299","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1093\/jac\/dkm003","volume":"59","author":"Torfoss D.","year":"2007","unstructured":"Torfoss D.; H\u00f8iby E.A.; Tangen J.M.; Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: A prospective, randomized, multicentre trial. J Antimicrob Chemother  2007,59(4),711-717","journal-title":"J Antimicrob Chemother"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jsps.2010.11.001","volume":"19","author":"Abdel-Bari A.","year":"2011","unstructured":"Abdel-Bari A.; Mokhtar M.S.; Sabry N.A.; El-Shafi S.A.; Bazan N.S.; Once versus individualized multiple daily dosing of aminoglycosides in critically ill patients. Saudi Pharm J  2011,19(1),9-17","journal-title":"Saudi Pharm J"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1592\/phco.30.3.248","volume":"30","author":"McDade E.J.","year":"2010","unstructured":"McDade E.J.; Wagner J.L.; Moffett B.S.; Palazzi D.L.; Once-daily gentamicin dosing in pediatric patients without cystic fibrosis. Pharmacotherapy  2010,30(3),248-253","journal-title":"Pharmacotherapy"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/jac\/45.3.383","volume":"45","author":"Bakri F.E.","year":"2000","unstructured":"Bakri F.E.; Pallett A.; Smith A.G.; Duncombe A.S.; Once-daily versus multiple-daily gentamicin in empirical antibiotic therapy of febrile neutropenia following intensive chemotherapy. J Antimicrob Chemother  2000,45(3),383-386","journal-title":"J Antimicrob Chemother"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/jac\/31.4.585","volume":"31","author":"Rozdzinski E.","year":"1993","unstructured":"Rozdzinski E.; Kern W.V.; Reichle A.; Once-daily versus thrice-daily dosing of netilmicin in combination with \u03b2-lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother  1993,31(4),585-589","journal-title":"J Antimicrob Chemother"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/00007691-200110000-00002","volume":"23","author":"Uijtendaal E.V.","year":"2001","unstructured":"Uijtendaal E.V.; Rademaker C.M.A.; Schobben A.F.A.M.; Once-daily versus multiple-daily gentamicin in infants and children. Ther Drug Monit  2001,23(5),506-513","journal-title":"Ther Drug Monit"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1183\/09031936.02.00221602","volume":"19","author":"Whitehead A.","year":"2002","unstructured":"Whitehead A.; Conway S.P.; Etherington C.; Caldwell N.A.; Setchfield N.; Bogle S.; Once-daily tobramycin in the treatment of adult patients with cystic fibrosis. Eur Respir J  2002,19(2),303-309","journal-title":"Eur Respir J"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1136\/adc.78.6.536","volume":"78","author":"Vic P.","year":"1998","unstructured":"Vic P.; Ategbo S.; Turck D.; Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis. Arch Dis Child  1998,78(6),536-539","journal-title":"Arch Dis Child"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1179\/joc.2008.20.3.324","volume":"20","author":"Coscia A.","year":"2008","unstructured":"Coscia A.; Maiorca D.; Martano C.; Use of netilmicin once or twice daily in preterm newborns: evaluation of nephrotoxicity by urinary \u03b11-microglobulin and retinol binding protein. J Chemother  2008,20(3),324-326","journal-title":"J Chemother"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"13","DOI":"10.5339\/qmj.2006.1.13","volume":"2006","author":"Al Ansari N.A.","year":"2006","unstructured":"Al Ansari N.A.; Foweraker J.; Mackeown D.; Bilton D.; Evaluation of once daily tobramycin versus the traditional three time daily for the treatment of acute pulmonary exacerbations in adult cystic fibrosis patients. Qatar Med J  2006,2006(1),13","journal-title":"Qatar Med J"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000239118","volume":"39","author":"Leoni F.","year":"1993","unstructured":"Leoni F.; Ciolli S.; Pascarella A.; Fanci R.; Caporale R.; Rossi Ferrini P.L.; Ceftriaxone plus conventional or single-daily dose amikacin versus ceftazidime\/amikacin as empiric therapy in febrile neutropenic patients. Chemotherapy  1993,39(2),147-152","journal-title":"Chemotherapy"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0140-6736(05)17906-9","volume":"365","author":"Smyth A.","year":"2005","unstructured":"Smyth A.; Tan K.H.V.; Hyman-Taylor P.; Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis\u2014the TOPIC study: A randomised controlled trial. Lancet  2005,365(9459),573-578","journal-title":"Lancet"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.mito.2013.10.005","volume":"16","author":"Singh R.","year":"2014","unstructured":"Singh R.; Sripada L.; Singh R.; Side effects of antibiotics during bacterial infection: Mitochondria, the main target in host cell. Mitochondrion  2014,16,50-54","journal-title":"Mitochondrion"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/0885066610377968","volume":"25","author":"Radigan E.A.","year":"2010","unstructured":"Radigan E.A.; Gilchrist N.A.; Miller M.A.; Management of aminoglycosides in the intensive care unit. J Intensive Care Med  2010,25(6),327-342","journal-title":"J Intensive Care Med"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","volume":"155","author":"Moore R.D.","year":"1987","unstructured":"Moore R.D.; Lietman P.S.; Smith C.R.; Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis  1987,155(1),93-99","journal-title":"J Infect Dis"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/00019048-199601000-00004","volume":"5","author":"Dew R.B.","year":"1996","unstructured":"Dew R.B.; Susla G.M.; Once-daily aminoglycoside treatment. Infect Dis Clin Pract  1996,5(1),12-24","journal-title":"Infect Dis Clin Pract"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1097\/00006454-200112000-00016","volume":"20","author":"Miron D.","year":"2001","unstructured":"Miron D.; Once daily dosing of gentamicin in infants and children. Pediatr Infect Dis J  2001,20(12),1169-1173","journal-title":"Pediatr Infect Dis J"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1128\/AAC.36.9.1951","volume":"36","author":"Barclay M.L.","year":"1992","unstructured":"Barclay M.L.; Begg E.J.; Chambers S.T.; Adaptive resistance following single doses of gentamicin in a dynamic in vitro model. Antimicrob Agents Chemother  1992,36(9),1951-1957","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jiph.2013.10.001","volume":"7","author":"Al-Hamad A.","year":"2014","unstructured":"Al-Hamad A.; Improving gentamicin dosing: A suggested approach to a simplified once-daily dosing schedule. J Infect Public Health  2014,7(3),247-248","journal-title":"J Infect Public Health"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1128\/AAC.31.7.1054","volume":"31","author":"Blaser J.","year":"1987","unstructured":"Blaser J.; Stone B.B.; Groner M.C.; Zinner S.H.; Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother  1987,31(7),1054-1060","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1086\/344653","volume":"36","author":"Drusano G.L.","year":"2003","unstructured":"Drusano G.L.; Prevention of resistance: A goal for dose selection for antimicrobial agents. Clin Infect Dis  2003,36(S1),S42-S50","journal-title":"Clin Infect Dis"},{"key":"ref=66","first-page":"1811","volume":"58","author":"Gonzalez L.S.","year":"1998","unstructured":"Gonzalez L.S.; Spencer J.P.; Aminoglycosides: A practical review. Am Fam Physician  1998,58(8),1811-1820","journal-title":"Am Fam Physician"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1097\/MCP.0b013e32833eebfd","volume":"16","author":"Prayle A.","year":"2010","unstructured":"Prayle A.; Smyth A.R.; Aminoglycoside use in cystic fibrosis: Therapeutic strategies and toxicity. Curr Opin Pulm Med  2010,16(6),604-610","journal-title":"Curr Opin Pulm Med"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.2146\/ajhp140564","volume":"72","author":"Stankowicz M.S.","year":"2015","unstructured":"Stankowicz M.S.; Ibrahim J.; Brown D.L.; Once-daily aminoglycoside dosing: An update on current literature. Am J Health Syst Pharm  2015,72(16),1357-1364","journal-title":"Am J Health Syst Pharm"},{"key":"ref=69","author":"Drew R.","year":"2014","unstructured":"Drew R.; Dosing and administration of parenteral aminoglycosides. In: UpToDate.  Available from:  https:\/\/medilib.ir\/uptodate\/show\/475#:~:text=INTRODUCTION%20%E2%80%94%20The%20traditional%20approach%20to,patients%20with%20normal%20renal%20function.2014"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1086\/515038","volume":"27","author":"Sexton D.J.","year":"1998","unstructured":"Sexton D.J.; Tenenbaum M.J.; Wilson W.R.; Steckelberg J.M.; Tice A.D.; Gilbert D.; Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group. Clin Infect Dis  1998,27(6),1470-1474","journal-title":"Clin Infect Dis"}],"container-title":["Current Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1566524023666230801160452","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/219360\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1566524023666230801160452","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T09:36:47Z","timestamp":1733737007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/219360\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":70,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1566524023666230801160452","relation":{},"ISSN":["1566-5240"],"issn-type":[{"value":"1566-5240","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}